Search for drugs:
Typing the drug name to query
DEXTROAMPHETAMINE SULFATE
DIR Classification
Classification:Moderate-DIR concern
Severity Score:2
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- OVERDOSAGE
- Individual patient response to amphetamines varies widely. While toxic symptoms occasionally occur as an idiosyncrasy at doses as low as 2 mg, they are rare with doses of less than 15 mg; 30 mg can produce severe reactions, yet doses of 400 to 500 mg are not necessarily fatal.
- In rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg.
- Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.
- Fatigue and depression usually follow the central stimulation.
- Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
Rhabdomyolysis
9
42903
Other ADRs
966
14116313
Odds Ratio = 3.066
Drug Property Information
ATC Code(s):
- N06BA02 - dextroamphetamine sulfate
- N06BA - Centrally acting sympathomimetics
- N06B - "PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS"
- N06 - PSYCHOANALEPTICS
- N - NERVOUS SYSTEM
Active Ingredient:dextroamphetamine sulfate
Active Ingredient UNII:JJ768O327N
Drugbank ID:DB01576
PubChem Compound:5826
CAS Number:51-64-9
Dosage Form(s):tablet
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
C[C@@H](CC1=CC=CC=C1)N
C[C@@H](CC1=CC=CC=C1)N
Reference
COHORT STUDY:
N/AOTHER REFERENCE(S):
N/ADisclaimer:
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.